Republished: Non-alcoholic Fatty Liver Disease: a Practical Approach to Treatment

Overview

Journal Postgrad Med J

Publisher Oxford University Press

Specialty General Medicine

Date 2015 Feb 7

PMID 25655252

Citations 7

Authors

J K Dyson

Q M Anstee

S McPherson

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) affects up to a third of the population in many developed countries. Between 10% and 30% of patients with NAFLD have non-alcoholic steatohepatitis (NASH) that can progress to cirrhosis. There are metabolic risk factors common to both NAFLD and cardiovascular disease, so patients with NASH have an increased risk of liver-related and cardiovascular death. Management of patients with NAFLD depends largely on the stage of disease, emphasising the importance of careful risk stratification. There are four main areas to focus on when thinking about management strategies in NAFLD: lifestyle modification, targeting the components of the metabolic syndrome, liver-directed pharmacotherapy for high risk patients and managing the complications of cirrhosis.

Citing Articles

Effects of Shenxiang Suhe Pill on coronary heart disease complicated with nonalcoholic fatty liver disease: A case-control study.

Ni J, Chen C, Tang J, Hu S, You Y, Zhang S Medicine (Baltimore). 2023; 101(49):e31525.

PMID: 36626456 PMC: 9750544. DOI: 10.1097/MD.0000000000031525.

Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis.

Minich A, Arisar F, Shaikh N, Herman L, Azhie A, Orchanian-Cheff A EClinicalMedicine. 2022; 50:101534.

PMID: 35812989 PMC: 9257342. DOI: 10.1016/j.eclinm.2022.101534.

Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease.

Neilson L, Macdougall L, Lee P, Hardy T, Beaton D, Chandrapalan S Frontline Gastroenterol. 2021; 12(7):578-585.

PMID: 34917315 PMC: 8640379. DOI: 10.1136/flgastro-2020-101480.

SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.

Tahara A, Takasu T Physiol Rep. 2019; 7(22):e14286.

PMID: 31782258 PMC: 6883099. DOI: 10.14814/phy2.14286.

A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy.

Bajantri B, Lvovsky D Gastroenterology Res. 2018; 11(3):252-259.

PMID: 29915639 PMC: 5997478. DOI: 10.14740/gr1033w.

References

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R . Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37(4):917-23. DOI: 10.1053/jhep.2003.50161. View

Malik S, deVera M, Fontes P, Shaikh O, Sasatomi E, Ahmad J . Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 2009; 15(12):1843-51. DOI: 10.1002/lt.21943. View

Dixon J, Bhathal P, OBrien P . Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121(1):91-100. DOI: 10.1053/gast.2001.25540. View

Calle E, Rodriguez C, Walker-Thurmond K, Thun M . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17):1625-38. DOI: 10.1056/NEJMoa021423. View

Kim C, Lim J, Lee W . Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 2001; 20(2):99-104. DOI: 10.7863/jum.2001.20.2.99. View

Newsome P, Allison M, Andrews P, Auzinger G, Day C, Ferguson J . Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut. 2012; 61(4):484-500. DOI: 10.1136/gutjnl-2011-300886. View

Thoma C, Day C, Trenell M . Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2011; 56(1):255-66. DOI: 10.1016/j.jhep.2011.06.010. View

Mummadi R, Kasturi K, Chennareddygari S, Sood G . Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008; 6(12):1396-402. DOI: 10.1016/j.cgh.2008.08.012. View

10.

Kirwan J, Solomon T, Wojta D, Staten M, Holloszy J . Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2009; 297(1):E151-6. PMC: 2711659. DOI: 10.1152/ajpendo.00210.2009. View

11.

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

12.

Garcia-Tsao G, Sanyal A, Grace N, Carey W . Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007; 46(3):922-38. DOI: 10.1002/hep.21907. View

13.

Harrison S, Fecht W, Brunt E, Neuschwander-Tetri B . Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2008; 49(1):80-6. DOI: 10.1002/hep.22575. View

14.

Hsieh S, Yoshinaga H, Muto T, Sakurai Y . Regular physical activity and coronary risk factors in Japanese men. Circulation. 1998; 97(7):661-5. DOI: 10.1161/01.cir.97.7.661. View

15.

Collier J, Ninkovic M, Compston J . Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002; 50 Suppl 1:i1-9. PMC: 1867644. DOI: 10.1136/gut.50.suppl_1.i1. View

16.

Al-Mallah M, Khawaja O, Sinno M, Alzohaili O, Abou Samra A . Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis. Cardiol J. 2010; 17(5):448-56. View

17.

Sjostrom L, Lindroos A, Peltonen M, Torgerson J, Bouchard C, Carlsson B . Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351(26):2683-93. DOI: 10.1056/NEJMoa035622. View

18.

Paschos P, Tziomalos K . Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol. 2013; 4(12):327-31. PMC: 3554795. DOI: 10.4254/wjh.v4.i12.327. View

19.

Chiu H, Ho S, Chen C, Yang C . Statin use and the risk of liver cancer: a population-based case–control study. Am J Gastroenterol. 2010; 106(5):894-8. DOI: 10.1038/ajg.2010.475. View

20.

Little J, Gillen J, Percival M, Safdar A, Tarnopolsky M, Punthakee Z . Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. J Appl Physiol (1985). 2011; 111(6):1554-60. DOI: 10.1152/japplphysiol.00921.2011. View